. 2022 Jul 19;8:82. doi: 10.1038/s41378-022-00400-3

Table 1.

Clinical performance of Epidax® benchmarked against commercial PCR platforms.

			Reference standard
			True positive	True negative	Sensitivity (%)	Specificity (%)
RT–qPCR	Epidax®	Positive	23	0	100	100
	Epidax®	Negative	0	20	100	100
	Bio–Rad	Positive	23	0	100	100
	Bio–Rad	Negative	0	20	100	100
End-point RT–PCR	Epidax® - Cycle 45	Positive	40	0	100	100
	Epidax® - Cycle 45	Negative	0	41	100	100
	Bio–Rad - Cycle 45	Positive	40	0	100	100
	Bio–Rad - Cycle 45	Negative	0	41	100	100
Direct RT–qPCR	Epidax®	Positive	23	0	96	100
	Epidax®	Negative	1	20	96	100
	Bio–Rad	Positive	24	2	100	90
	Bio–Rad	Negative	0	18	100	90
Direct End-point RT–PCR	Epidax® - Cycle 45	Positive	23	1	96	95
	Epidax® - Cycle 45	Negative	1	19	96	95
	Bio–Rad - Cycle 45	Positive	24	3	100	85
	Bio–Rad - Cycle 45	Negative	0	17	100	85
RT-LAMP	Epidax®	Positive	18	0	–	100
	Epidax®	Negative	12	24	–	100
	Proflex	Positive	18	0	–	100
	Proflex	Negative	12	24	–	100

Note that the overall sensitivity of the RT-LAMP assay is not calculated due to the limited spread of Ct values of the positive samples available (as shown in Fig. 4a, b, there are two distinct groups of Ct values)